144 results on '"Hiemke, C."'
Search Results
2. Therapeutic reference range for aripiprazole revised: A systematic review and combined analysis
3. Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range
4. The therapeutic reference range for olanzapine revised – how to combine old and new findings
5. Patterns of clozapine pharmacokinetics in patient subgroups with different body mass index
6. Dose-related reference range of neuro-/psychoactive drugs in children and adolescents
7. The clinical relevance of the pharmacological interaction between clozapine and sertraline
8. The effect of pharmacological interaction between a proton pump inhibitor pantoprazole and clozapine
9. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
10. Plasma levels of benperidol, prolactin, and homovanillic acid after intravenous versus two different kinds of oral application of the neuroleptic in schizophrenic patients
11. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
12. Effect of triglyceride and total cholesterol levels on the pharmacokinetics of clozapine in clozapine medicated patients
13. Pharmacokinetic considerations of different dosing regimens in clozapine medicated patients
14. How to find the therapeutic reference range for psychoactive drugs
15. Pharmacokinetic considerations in coprescription of perazine in risperidone medicated patients
16. Psychopharmacotherapy during pregnancy: Therapeutic drug monitoring (tdm) in maternal blood, amniotic fluid and umbilical cord blood
17. Concentrations of Venlafaxine, Mirtazapine and Citalopram in serum and cerebrospinal fluid – a naturalistic approach
18. Duloxetine enters the brain – but why is it not found in the cerebrospinal fluid
19. Retrospective Pilot Study for Analysis of Antidepressant Serum Concentrations of Citalopram and Venlafaxine during Inflammation
20. Risk of Bleeding Related to Selective and Non-selective Serotonergic Antidepressants: A Case/Non-case Approach Using Data from Two Pharmacovigilance Databases
21. Influence of Concomitant Medications on the Total Clearance and the Risk for Supra-therapeutic Plasma Concentrations of Citalopram. A Population-Based Cohort Study
22. Pharmakotherapie im Alter
23. Retrospective analysis of Therapeutic Drug Monitoring data from patients with a bipolar disorder who are treated with lamotrigine
24. Alteration of risperidone elimination during acute inflammation, two cases
25. Therapeutic drug monitoring for improved psychopharmacotherapy in elderly patients
26. Therapeutic drug monitoring for patients with bipolar disorders. Useful or useless?
27. Melperone but not metoprolol is a clinically relevant inhibitor of CYP2D6
28. Therapeutic Drug Monitoring in maternal serum, amniotic fluid and umbilical cord blood during pregnancy and delivery
29. Key Lecture
30. Concentrations of different antidepressants in plasma and cerebrospinal fluid of patients treated under naturalistic conditions
31. TDM in psychiatric hospitals. Data from a German survey
32. Prediction of Antidepressant Response to Venlafaxine by a Combination of Early Response Assessment and Therapeutic Drug Monitoring
33. Therapeutic Drug Monitoring of Zuclopenthixol in a Double-Blind Placebo-Controlled Discontinuation Study in Adults with Intellectual Disabilities and Aggressive Behaviour
34. Early Improvement and Serum Concentrations of Citalopram to Predict Antidepressant Drug Response of Patients with Major Depression
35. Effects of concomitant cytochrome P450 inhibitors on the metabolism of citalopram: Analysis of data from routine therapeutic drug monitoring (TDM)
36. Influence of the body mass index on serum levels of venlafaxine and its active metabolite O-desmethylvenlafaxine. Analysis of a large therapeutic drug monitoring database
37. Evaluation of a risk-scale for drug-induced QT-prolongation in elderly psychiatric inpatients
38. Therapeutic Drug Monitoring (TDM) of donepezil in patients with Alzheimers dementia
39. Age-dependency of psychotropic drug-induced anticholinergic adverse reactions: Analysis of reports to the pharmacovigilance system AGATE
40. Induction of p-gp affects pharmacodynamics of its substrates
41. Therapeutic drug-monitoring for opiate-dependent patients receiving buprenorphine for substitution
42. Therapeutic Drug Monitoring (TDM) in maternal serum, amniotic fluid and umbilical cord blood during pregnancy and delivery
43. Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid under naturalistic conditions
44. Agomelatine and Hepatotoxicity: Implications of Cumulated Data Derived from Spontaneous Reports of Adverse Drug Reactions
45. Pharmacodynamic Effects of Aripiprazole and Ziprasidone with Respect to P-Glycoprotein Substrate Properties
46. Evaluation of a risk-scale for anticholinergic side-effects in elderly psychiatric inpatients
47. Therapeutic drug monitoring (TDM) in plasma and amniotic fluid in pregnancy
48. Therapeutic drug monitoring (TDM) and clinical outcomes in forensic patients under clozapine therapy compared to therapies with other antipsychotic drugs
49. Citation of the AGNP consensus guidelines for therapeutic drug monitoring in psychiatry 2004 in the scientific literature 2004 to 2011
50. Cost-effectiveness potential of therapeutic drug monitoring for depressed inpatients treated with citalopram by shortening of hospitalization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.